We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Johnson & Johnson, Roche Holding, Raytheon Technologies, Intuit and Target
Read MoreHide Full Article
For Immediate Release
Chicago, IL – April 22, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Johnson & Johnson (JNJ - Free Report) , Roche Holding AG (RHHBY - Free Report) , Raytheon Technologies Corp. (RTX - Free Report) , Intuit Inc. (INTU - Free Report) and Target Corp. (TGT - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Top Research Reports for Johnson & Johnson, Roche and Raytheon
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson, Roche Holding AG, and Raytheon Technologies Corp. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of Johnson & Johnson have modestly outperformed the Zacks Large Cap Pharmaceuticals industry over the year-to-date period (+7.4% vs. +6.7%). The company's pharma unit is performing at above-market levels, supported by its blockbuster drugs, Darzalex and Stelara, and contribution from newer drugs, Erleada and Tremfya. Sales in the MedTech unit recovered in Q1 and the company is focusing on growing this business through new products.
However, sales in the Consumer unit are being hurt by external supply constraints. J&J is making rapid progress with its pipeline and line extensions. Headwinds like generic competition and pricing pressure continue. Though J&J has taken meaningful steps to resolve its talc and opioid litigation, they continue to remain an overhang on the stock.
Roche shares have gained +17.4% over the past year against the Zacks Large Cap Pharmaceuticals industry's gain of +28.8%. The company's strong demand for coronavirus tests, recently launched drugs and diagnostics platforms has led to a strong performance. The Zacks analyst believes that the core pharmaceuticals business is showing signs of recovery from COVID-19 disruptions. The diagnostics division maintains its stellar performance on strong demand for COVID-19 tests and other diagnostics platforms.
Strong growth in Ocrevus, Evrysdi, Tecentriq and Hemlibra continues to counter biosimilar competition for legacy drugs like Herceptin, Avastin and MabThera. Approval of new drugs should also boost the top line. However, biosimilar competition for key drugs weighs on its performance. The decline in sales of legacy drugs due to generic competition has also affected revenues.
Shares of Raytheon have outperformed the Zacks Aerospace - Defense Equipment industry over the past year (+33.9% vs. +17.8%). The company continues to receive ample orders for its combat-proven defense products from the Pentagon. The Zacks analyst believes that both domestic and international program growth to remain robust for its defense business in the coming days. The SEAKR Engineering acquisition is expected to bolster Raytheon's space-based capabilities and would bring in improved synergies.
The stock holds a solid solvency position, at least in the near term. However, the outbreak of the Omicron variant has once again impacted demand in the commercial aerospace market, which in turn may hurt Raytheon's Pratt & Whitney and Collins Aerospace segments. Purchase order declines also pose a risk to the stock.
Other noteworthy reports we are featuring today include Intuit Inc. and Target Corp.
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Johnson & Johnson, Roche Holding, Raytheon Technologies, Intuit and Target
For Immediate Release
Chicago, IL – April 22, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Johnson & Johnson (JNJ - Free Report) , Roche Holding AG (RHHBY - Free Report) , Raytheon Technologies Corp. (RTX - Free Report) , Intuit Inc. (INTU - Free Report) and Target Corp. (TGT - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Top Research Reports for Johnson & Johnson, Roche and Raytheon
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson, Roche Holding AG, and Raytheon Technologies Corp. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Shares of Johnson & Johnson have modestly outperformed the Zacks Large Cap Pharmaceuticals industry over the year-to-date period (+7.4% vs. +6.7%). The company's pharma unit is performing at above-market levels, supported by its blockbuster drugs, Darzalex and Stelara, and contribution from newer drugs, Erleada and Tremfya. Sales in the MedTech unit recovered in Q1 and the company is focusing on growing this business through new products.
However, sales in the Consumer unit are being hurt by external supply constraints. J&J is making rapid progress with its pipeline and line extensions. Headwinds like generic competition and pricing pressure continue. Though J&J has taken meaningful steps to resolve its talc and opioid litigation, they continue to remain an overhang on the stock.
(You can read the full research report on Johnson & Johnson here >>>)
Roche shares have gained +17.4% over the past year against the Zacks Large Cap Pharmaceuticals industry's gain of +28.8%. The company's strong demand for coronavirus tests, recently launched drugs and diagnostics platforms has led to a strong performance. The Zacks analyst believes that the core pharmaceuticals business is showing signs of recovery from COVID-19 disruptions. The diagnostics division maintains its stellar performance on strong demand for COVID-19 tests and other diagnostics platforms.
Strong growth in Ocrevus, Evrysdi, Tecentriq and Hemlibra continues to counter biosimilar competition for legacy drugs like Herceptin, Avastin and MabThera. Approval of new drugs should also boost the top line. However, biosimilar competition for key drugs weighs on its performance. The decline in sales of legacy drugs due to generic competition has also affected revenues.
(You can read the full research report on Roche here >>>)
Shares of Raytheon have outperformed the Zacks Aerospace - Defense Equipment industry over the past year (+33.9% vs. +17.8%). The company continues to receive ample orders for its combat-proven defense products from the Pentagon. The Zacks analyst believes that both domestic and international program growth to remain robust for its defense business in the coming days. The SEAKR Engineering acquisition is expected to bolster Raytheon's space-based capabilities and would bring in improved synergies.
The stock holds a solid solvency position, at least in the near term. However, the outbreak of the Omicron variant has once again impacted demand in the commercial aerospace market, which in turn may hurt Raytheon's Pratt & Whitney and Collins Aerospace segments. Purchase order declines also pose a risk to the stock.
(You can read the full research report on Raytheon here >>>)
Other noteworthy reports we are featuring today include Intuit Inc. and Target Corp.
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.